Opus Genetics, Inc. Accrued Liabilities, Current
Opus Genetics, Inc. (IRD) had Accrued Liabilities, Current of $4.49 million as of 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-03-12
- 2025-12-31: Accrued Liabilities, Current $4.49M.
- 2024-12-31: Accrued Liabilities, Current $8.15M; Accrued Liabilities, Current as first filed $8.14M.
- 2024-09-30: Accrued Liabilities, Current $5.17M.
- 2024-06-30: Accrued Liabilities, Current $3.49M.
| Period end | Accrued Liabilities, Current | Accrued Liabilities, Current as first filed |
|---|---|---|
| 2025-12-31 | $4.49M 10-K · filed 2026-03-12 | |
| 2024-12-31 | $8.15M 10-K · filed 2026-03-12 | $8.14M 10-K · filed 2025-03-31 |
| 2024-09-30 | $5.17M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $3.49M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $3.65M 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $1.81M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $1.93M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $3.44M 10-Q · filed 2023-08-11 | |
| 2023-03-31 | $1.93M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $1.68M 10-K · filed 2024-03-08 | |
| 2022-09-30 | $1.22M 10-Q · filed 2022-11-04 | |
| 2022-06-30 | $1.42M 10-Q · filed 2022-08-12 | |
| 2022-03-31 | $1.42M 10-Q · filed 2022-05-13 | |
| 2021-12-31 | $1.73M 10-K · filed 2023-03-30 | |
| 2021-09-30 | $1.20M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $1.20M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $895.00K 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $1.97M 10-K · filed 2022-03-24 | |
| 2019-12-31 | $621.00K 10-K · filed 2021-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |